

Check for updates

Article

Hypnosis in Breast Cancer Care: A Systematic Review of Randomized Controlled Trials

Integrative Cancer Therapies 2015, Vol. 14(1) 5–15 © The Author(s) 2014 Reprints and permissions: sagepub.com/journalsPermissions.nav DOI: 10.1177/1534735414550035 ict.sagepub.com



Holger Cramer, PhD¹, Romy Lauche, PhD¹, Anna Paul, PhD¹, Jost Langhorst, MD¹, Sherko Kümmel, MD², and Gustav J. Dobos, MD¹

Abstract

Introduction. Many breast cancer patients and survivors experience pain and emotional stress related to their disease, its diagnostic procedures, or treatment. Hypnosis has long been used for the treatment of such symptoms. The aim of this review was to systematically assess the effectiveness of hypnosis in women with breast cancer, breast cancer survivors, and in women undergoing diagnostic breast biopsy. Methods. PubMed, Scopus, the Cochrane Library, PsycINFO, and CAMBASE were screened through February 2014 for randomized controlled trials (RCTs) of hypnosis in women with breast cancer or undergoing diagnostic breast biopsy. RCTs on postmenopausal women without a history of breast cancer were also eligible. Primary outcomes were pain, distress, fatigue, nausea/vomiting, and hot flashes. Safety was defined as secondary outcome measure. Risk of bias was assessed by 2 reviewers independently using the Cochrane Risk of Bias Tool. Results. Thirteen RCTs with 1357 patients were included. In women undergoing diagnostic breast biopsy (3 RCTs), hypnosis positively influenced pain and distress; I RCT on breast cancer surgery found effects of hypnosis on pain, distress, fatigue, and nausea. For women undergoing radiotherapy (3 RCTs), hypnosis combined with cognitive-behavioral therapy improved distress and fatigue. In 3 RCTs on women with and without a history of breast cancer experiencing hot flashes, hypnosis improved hot flashes and distress. Three RCTs on women with metastatic breast cancer found effects on pain and distress. Conclusions. This systematic review found sparse but promising evidence for the effectiveness of hypnosis in breast cancer care. While more research is needed to underpin these results, hypnosis can be considered as an ancillary intervention in the management of breast cancer-related symptoms.

Keywords

breast neoplasms, hypnosis, radiotherapy, cancer survivors, surgery, review

Introduction

With more than 1.6 million new cases in 2012, breast cancer is the most frequent cancer in women worldwide. Twentyfive percent of all female cancer cases were diagnosed with breast cancer.1 Due to improved diagnosis and treatment, there is a continuous increase in survival rates.² However, invasive diagnostic procedures and anticancer treatment are often associated with serious side effects. Breast biopsy, lumpectomy, and mastectomy often induce psychological distress, pain, and, mainly due to anesthesia, nausea and vomiting.³⁻⁷ Chemotherapeutic and radiotherapeutic breast cancer treatment are strongly associated with psychological distress, fatigue, and, in the case of chemotherapy, nausea and vomiting. 8-10 Substantial psychological distress is present in 1 out of every 3 breast cancer patients. 10-12 These symptoms often persist for years after completion of treatment. 11,12 Moreover, many breast cancer survivors experience hot flashes as a result of chemotherapeutic and/or antihormonal treatment.¹³ Besides personal grief, some of these symptoms can prolong hospital stay and thereby increase costs of medical care.¹⁴ Management of symptoms related to breast cancer, its diagnostic procedures, and treatment is therefore gaining increased importance.

¹Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany ²Interdisclipinary Breast Cancer Center, Kliniken Essen-Mitte, Essen, Germany

Corresponding Author:

Holger Cramer, Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Am Deimelsberg 34a 45276 Essen, Germany. Email: h.cramer@kliniken-essen-mitte.de

Hypnosis includes the use of suggestions for alterations in perception, sensation, emotion, thought, or behavior.¹⁵ The suggestions used in hypnosis can be direct or permissive. 16 Hypnosis has long been utilized in medical settings for the control of pain and distress.¹⁷ Suggestions for control of pain and its related distress mostly ask patients to transform the perception of pain and to disentangle the somatic sensation of pain from its emotional components.¹⁷ Accordingly, it has been found that hypnosis can reduce both clinical and experimental pain. 18 It has also been suggested that hypnosis might be useful in reducing chemotherapy-related side effects such as anticipatory nausea and vomiting by reducing conditioning effects and treatmentrelated distress. 19 A mediator that has been shown to play a role in the effects of hypnosis on breast cancer-related issues²⁰ are response expectancies, that is, expectancies for the occurrence of nonvolitional responses, such as pain, nausea, or anxiety. Hypnotic response expectancies are related to the belief that one is capable of experiencing a suggested effect.21

The aim of this review was to systematically assess the effectiveness of hypnosis in women with breast cancer, breast cancer survivors, and in women undergoing diagnostic breast biopsy.

Methods

PRISMA guidelines for systematic reviews and metaanalyses²² and the recommendations of the Cochrane Collaboration²³ were followed.

Literature Search

PubMed/Medline, the Cochrane Library, CAMBASE, and PsycINFO were searched from their inception until February 25, 2014, without language restrictions. The complete search strategy for Medline was as follows: (breast[MeSH Terms] OR "breast neoplasms" [MeSH Terms] OR "breast cancer" [Title/Abstract] OR breast[Title/ Abstract]) AND (hypnosis [MeSH Terms] OR hypnosis [Title/ Abstract] OR hypnotherapy[Title/Abstract]). The search strategy was adapted for each database as necessary. Additionally, reference lists of identified original and review articles were searched manually. Abstracts of identified records were screened, and the full articles of potentially eligible studies were read in full by 2 authors to determine whether they met the eligibility criteria.

Eligibility Criteria

To be eligible, studies had to meet the following criteria:

 Types of studies. Randomized controlled trials (RCTs) were eligible. Studies were eligible only if they were published as a full article.

- 2. Types of participants. Studies of adult (older than 18 years) women with breast cancer, breast cancer survivors, and women who were undergoing diagnostic breast biopsy were eligible. Given that effects of therapeutic interventions for hot flashes are comparable in women with and without a history of breast cancer, it was post hoc decided to also include studies on postmenopausal women with hot flashes without prior breast cancer.
- 3. Types of interventions. Studies that compared hypnosis to standard care, attention control, or any active intervention were eligible. Studies in which hypnosis was combined with other psychological interventions were also eligible but were analyzed separately. Both studies with live administration and taped administration of hypnosis were eligible.
- Types of outcomes. Studies were eligible if they assessed pain, distress, fatigue, nausea/vomiting, or hot flashes. Safety was defined as secondary outcome measure.

Data Extraction

Two reviewers independently extracted data on characteristics of the study (eg, trial design, randomization, blinding), characteristics of the patient population (eg, type of diagnostic/therapeutic procedure, sample size, age), characteristics of the intervention and control (eg, type of hypnosis, type of control intervention), outcome measures, and results.

Due to the broad inclusion criteria that were expected to result in a heterogeneous sample of RCTs, a meta-analysis was neither planned nor conducted.

Risk of Bias in Individual Studies

Risk of bias was assessed by 2 reviewers independently. The criteria recommended in the Cochrane Risk of Bias Tool were used.²³ This tool assesses risk of bias on the following domains: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias (rated as low risk, high risk, or unclear). Discrepancies were rechecked with a third reviewer and consensus achieved by discussion.

Results

Literature Search

Three hundred and thirty-three records were retrieved in literature search, and 16 full-text articles were assessed for eligibility²⁵⁻⁴⁰ (Figure 1). Two articles were excluded because they included women undergoing elective breast surgery.^{25,26} Another article was excluded because it was not randomized.²⁷ Thirteen RCTs with a total of 1357 patients were included in the review.²⁸⁻⁴⁰

Cramer et al 7




Figure 1. Flowchart of the results of the literature search.

Study Characteristics

Characteristics of the sample, interventions, outcome measures, and results are shown in Table 1.

Setting and Participant Characteristics. All included RCTs except one³¹ were conducted in the United States. Patients were recruited from large medical centers or community oncologists. Four studies included women who were referred to diagnostic image-guided large core needle biopsy³² or excisional biopsy.^{34,35,38} One of those studies also included women with breast cancer who underwent lumpectomy.³⁵ Three studies included patients undergoing breast cancer radiotherapy^{36,37,39}; 2 studies included women with metastatic breast cancer^{28,40}; 2 studies included breast cancer survivors experiencing hot flashes^{29,33}; and 1 study included women without a history of breast cancer who experienced hot flashes.³⁰ Patients' mean age ranged from 46.4 to 58.2 years.

Intervention Characteristics. All studies used live administered standardized hypnotic procedures. Suggestions mainly addressed relaxation, imagery, and symptom control. All interventions also included guidance for self-hypnosis. One study provided the full script used for intervention as appendix.³² Seven studies used single intervention sessions.³²⁻³⁹ Six of those studies reported length of the intervention.³⁴⁻³⁹ Median intervention length was 15 minutes (range = 10-15 minutes). Three studies also included cognitive—behavioral therapy sessions.^{36,37,39} The 3 studies on women experiencing hot flashes used multiple sessions.^{29,30,33} Over a period of 3 to 5 (median = 5) weeks, 1 weekly 50 to 60 (median = 50)-minute session was offered. Two studies on metastatic breast cancer combined hypnosis or self-hypnosis with support groups. Over a period of 12 months, 1 weekly 90-minute session of hypnosis and

group support was offered.^{28,40} The third study on metastatic breast cancer used self-hypnosis over a period of 4 weeks.³¹ Hypnosis was administered by clinical psychologists, ^{28,29,34,36,38} counsellors, ⁴⁰ students, ³² or physicians.^{28,32,40}

Ten studies had 1 control arm^{28-30,33-39} and 3 studies had 2 control arms.^{31,32,40} Six studies compared hypnosis to standard care or no treatment.^{29,32,34,36,39,40} Five studies compared hypnosis to a standardized attention control condition.^{30,32,34,37} For attention control, empathic attentive behaviors without specific interventions were used. Attention control was matched for time length in all 5 studies. One study each compared hypnosis combined with support groups to self-directed education²⁸ or support groups alone.⁴⁰ One study compared self-hypnosis to Johrei, a Japanese visualization technique³¹; and 1 study compared hypnosis to Gabapentin.³³

Outcome Measures. Pain was assessed in 5 studies, using a verbal rating scale, ³² a numerical rating scale, ⁴⁰ a visual analog scale, ^{34,36} or the pain rating scale. ²⁸ Eight studies assessed distress, using a verbal rating scale, ³² visual analog scale, ^{34,35,38} the Mood Report Form, ³⁹ the Center for Epidemiologic Studies Depression Scale, ²⁹ the Hospital Anxiety and Depression Scale, ²⁹ the Profile of Moods States, ^{31,40} the Beck Depression Inventory, ³¹ or the State-Trait Anxiety Inventory. ³¹ Two studies assessed fatigue using the Functional Assessment of Chronic Illness Therapy–Fatigue and daily visual analog scales ^{36,37}; 1 study used a visual analog scale to study nausea ³⁵; and 3 studies studied hot flashes using the Hot Flash Related Daily Interference Scale, ^{29,30,33} diaries, ^{30,33} and/or objective measures (a skin conductance monitoring system). ³⁰ Adverse events were reported by 5 studies. ^{30,32,33,37,39} Four further studies reported health reasons for dropouts. ^{28,29,31,40}

Risk of Bias in Individual Studies. Overall, most included studies had low risk of bias. Randomization was adequate in all but 3 studies in which group allocation was based on day of surgery³⁴ or unclear.^{31,40} Only 3 studies reported adequate allocation concealment^{32,36,39} (Table 2). No study reported blinding of patients or care providers, but 4 studies reported adequate blinding of outcome assessors.^{34,38,39} Risk of attention bias was low in all studies but those on metastatic breast cancer that reported high rates of health-related dropouts.^{28,31,40}

Outcomes

Women Undergoing Diagnostic Breast Biopsy. Four RCTs reported reduced pre-,³⁸ peri-,³² or postoperative^{34,35} pain intensity and psychological distress after preoperative hypnosis compared to attention control. Decreased postoperative pain and psychological distress compared to standard care was reported in 1 RCT.³⁶ One study reported

Results: (1) Pain; (2) Distress; (3) Fatigue; (4) Nausea/Yomiting; (5) Hot Flashes; (6) Safety	(1) Smaller increase in hypnosis than in education (ES NR, P = .034) (2) NA (3) NA (4) NA (5) NA (6) 4 (hypnosis) vs 9 (education) died or were too ill to complete questionnaires	(1) NA (2) Larger decrease in hypnosis than in no treatment (ES $\eta_p^2 = 0.217$, $P < .005$) (3) NA (4) NA (5) Larger decrease in hypnosis than in no treatment (ES $\eta_p^2 = 0.479$, $P < .001$) (6) No dropouts due to adverse effects	 (1) NA (2) NA (3) NA (4) NA (5) Larger decrease in hypnosis than in attention control (ES d = 0.52 to 1.25, P < .001) (6) no AE related to the intervention 	 (1) NA (2) Larger decrease in hypnosis than in usual care (ES NR, P < .04) (3) NA (4) NA (5) NA (6) 2 deaths in each group
Outcome Measures: (1) Pain; (2) Distress; (3) Fatigue; (4) Nausea/Vomiting; (5) Hot Flashes; (6) Safety	(1) Pain Rating Scale (2) NA (3) NA (4) NA (5) NA (6) Dropouts	(1) NA (2) CES-D, HADS-A (3) NA (4) NA (5) HFRDIS (6) Dropouts	(1) NA (2) NA (3) NA (4) NA (5) Hot flashes frequency, intensity; HFRDIS (6) Adverse events	(1) NA (2) POMS, BDI, STAI (3) NA (4) NA (5) NA (6) Dropouts
Type of Control Condition	Self-directed education material	No treatment	Attention control: Discussion with therapists, structured manual 5 weeks, once weekly	(1) Johrei, 4 weeks, frequency unclear (2) Usual care
Type of Intervention	Hypnosis plus supportive-expressive therapy 12 months, once weekly + Self-directed education material	Hypnosis Live administration, standardized hypnotic induction 5 weeks, once weekly	Hypnosis Live administration, individualized hypnotic suggestions 5 weeks, once weekly + daily home practice via audio recording	Self-hypnosis Administration unclear 4 weeks, frequency unclear
Mean Age (SD)	52.7 (10.5) (Hypnosis) 53.1 (10.8) (Control)	55.8 (SD NR) (Hypnosis) 58.2 (SD NR) (No treatment)	54.5 (SD NR) (Hypnosis) 54.7 (SD NR) (Control)	w Z
Sample Size, No. of Groups	N = 125 2 groups (N in individual intervention groups NR)	N = 60 2 groups (N in individual intervention groups NR)	N = 187 2 groups (N = 93 in hypnosis; N = 94 in attention control)	N = 37 3 groups (N in individual intervention groups NR)
Sample	Women with metastatic breast cancer	Breast cancer survivors	Postmenopausal women	Women with metastatic breast cancer
Authors, Year	Butler et al, 2009 ²⁸	Elkins et al, 2008 ²⁹	Elkins et al, 2012³0	Laidlaw et al, 2005³¹

(continued)

Table I. (continued)

Results: (1) Pain; (2) Distress; (3) Fatigue; (4) Nausea/Yomiting; (5) Hot Flashes; (6) Safety	(1) Smaller increase in hypnosis than in standard care (ES NR, $P = .018$) (2) Smaller increase in hypnosis than in standard care (ES NR, $P < .001$); larger decrease in hypnosis than in attention control (ES NR, $P < .01$) (3) NA (4) NA (5) NA (6) NS	(1) NA (2) NA (3) NA (4) NA (5) NS (6) 3 adverse events in control group	(1) Larger decrease in hypnosis than in standard care (ES NR, <i>P</i> < .001) (2) Larger decrease in hypnosis than in standard care (ES NR, <i>P</i> < .001) (3) NA (4) NA (5) NA (6) NA	(1) Larger decrease in hypnosis than in attention control (ES $d = 0.82$, $P < .001$) (2) Larger decrease in hypnosis than in attention control (ES $d = 0.91$, $P < .001$) (3) Larger decrease in hypnosis than in attention control (ES $d = 0.84$, $P < .001$) (4) Larger decrease in hypnosis than in attention control (ES $d = 0.78$, $P < .001$) (5) NA (6) NA
Outcome Measures: (1) Pain; (2) Distress; (3) Fatigue; (4) Nausea/Yomiting; (5) Hot Flashes; (6) Safety	(1) Verbal 0-10 scale (2) Verbal 0-10 scale (3) NA (4) NA (5) NA (6) Safety	(1) NA (2) NA (3) NA (4) NA (5) Hot flashes frequency; HFRDIS (6) Adverse events	(i) vAS (2) vAS (3) vAS (4) vA (5) vA (6) vA	(i) vas (2) vas (3) vas (4) vas (5) na (6) na
Type of Control Condition	(1) Standard care (2) Attention control: Structured attentive behavior Single session	Gabapentin, 900 mg daily	Standard care	Attention control Structured attentive behavior Single session
Type of Intervention	Hypnosis Live administration, standardized hypnotic induction Single session	Hypnosis Live administration, individualized hypnotic suggestions 3 weeks, once weekly + home practice via audio recording	Hypnosis Live administration, standardized hypnotic induction Single session	Hypnosis Live administration, standardized hypnotic induction Single session
Mean Age (SD)	ž	NR (Hypnosis) NR (Control)	50.1 (10.9)	48.7 (12.9) (Hypnosis) 48.3 (13.3) (Control)
Sample Size, No. of Groups	N = 240 3 groups (N = 80 in hypnosis; N = 78 in standard care; N = 82 in attention control)	N = 27 2 groups (N = 13 in hypnosis; N = 14 in gabapentin)	N = 20 2 groups (N in individual intervention groups NR)	N = 200 2 groups (N = 105 in hypnosis; N = 95 in attention control)
Sample	Women undergoing diagnostic large core needle biopsy	Breast cancer survivors; Women with increased risk at developing breast cancer	Women undergoing diagnostic excisional breast biopsy	Women undergoing diagnostic excisional breast biopsy and women with breast cancer undergoing lumpectomy
Authors, Year	Lang et al, 2006 ³²	MacLaughlan David et al, 2013³³	Montgomery et al, 2002 ³⁴	Montgomery et al, 2007³§

ss; (3) (5) Hot	sis than = .01) s circal	69 to 69 to sis	sis than = 0.67	sis than o < .03)
Results: (1) Pain; (2) Distress; (3) Fatigue; (4) Nausea/Vomiting; (5) Hot Flashes; (6) Safety	(1) NA (2) NA (3) Larger decrease in hypnosis than in standard care (ES NR, P = .01) (4) NA (5) NA (6) I (hypnosis) vs 2 dropouts (standard care) due to medical reasons	(1) NA (2) NA (3) Larger decrease in hypnosis than in attention control (ES 0.69 to 1.69, P < .001) (4) NA (5) NA (6) No AE in CBT plus hypnosis	(1) NA (2) Larger decrease in hypnosis than in attention control (ES d = 0.67 to 0.85, P < .002) (3) NA (4) NA (5) NA (6) NA (6) NA	(1) NA (2) Larger decrease in hypnosis than in standard care (ES NR, P < .03) (3) NA (4) NA (5) NA (5) NA (6) No adverse effects
esults: (1) Pai gue; (4) Naus Flashes	NA NA Larger decree in standard cc NA NA I (hypnosis) v (standard car	NA NA Larger decreas in attention co 1.69, P < .001) NA NA NO AE in CBT	NA Larger decrease i in attention contr to 0.85, P < .002) NA NA NA	(1) NA (2) Larger decrease in in standard care (E) (3) NA (4) NA (5) NA (6) NA (6) NA (7) NA (8) NA (9) NA
	(1) NA (2) NA (3) Large in sta (4) NA (5) NA (6) I (hy (stan reass	(1) NA (2) NA (3) Large in at 1.69, NA (5) NA (6) No	(1) NA (2) Large (2) Large (3) NA (4) NA (5) NA (6) NA (6) NA	(1) NA (2) Larg in st (3) NA (4) NA (5) NA (6) No (
Outcome Measures: (1) Pain; (2) Distress; (3) Fatigue; (4) Nausea/Vomiting; (5) Hot Flashes; (6) Safety	(I) NA (2) NA (3) FACIT-F, VAS (4) NA (5) NA (6) Dropouts	(1) NA (2) NA (3) FACIT-F, VAS (4) NA (5) NA (6) Adverse events	(1) NA (2) <as (3) NA (4) NA (5) NA (6) NA</as 	(I) NA (2) Mood Report Form (3) NA (4) NA (5) NA (6) Safety
Type of Control Condition	Standard care	Attention control Structured attentive behavior During radiotherapy, twice weekly	Attention control Structured attentive behavior Single session	Standard care
Type of Intervention	(1) Hypnosis Live administration, standardized hypnotic induction Single session and CD combined with (2) Cognitive— behavioral therapy 6 weeks, twice weekly	Cognitive—behavioral therapy (CBT) plus hypnosis Individual format live CBT Hypnosis: Live administration, standardized hypnotic induction During radiotherapy, twice weekly	Hypnosis Live administration, standardized hypnotic induction Single session	(1) Hypnosis Live administration, standardized hypnotic induction Single session and CD combined with (2) Cognitive- behavioral therapy 5 weeks, twice weekly
Mean Age (SD)	53.5 (10.4) (Hypnosis) 52.8 (11.7) (Control)	55.6 (9.7) (Hypnosis) 56.0 (11.9) (Control)	46.4 (13.3) (Hypnosis) 48.3 (14.1) (Control)	X X
Sample Size, No. of Groups	N = 45 2 groups (N = 23 in hypnosis; N = 22 in standard care)	N = 200 2 groups (N = 100 in hypnosis; N = 100 in attention control)	N = 90 2 groups (N = 49 in hypnosis; N = 41 in attention control)	N = 44 2 groups (N = 22 in hypnosis; N = 22 standard care)
Sample	Women with breast cancer undergoing radiotherapy	Women with breast cancer undergoing radiotherapy	Women undergoing diagnostic excisional breast biopsy	Women with breast cancer undergoing radiotherapy
Authors, Year	Montgomery et al, 200936	Montgomery et al, 2014 ³⁷	Schnur et al, 2008³8	Schnur et al, 2009 ³⁹

Table I. (continued)

Authors, Year	Sample	Sample Size, No. of Groups	Mean Age (SD)	Type of Intervention	Type of Control Condition	Outcome Measures: (1) Pain; (2) Distress; (3) Fatigue; (4) Nausea/Vomiting; (5) Hot Flashes; (6) Safety	Results: (1) Pain; (2) Distress; (3) Fatigue; (4) Nausea/Yomiting; (5) Hot Flashes; (6) Safety
Spiegel et al, 1983 ⁴⁰	Women with metastatic breast cancer	N = 86 2 groups (N in hypnosis and psychological support NR; N = 36 in usual care)	ž	Self-hypnosis plus psychological support group 12 months, once weekly	(1) Psychological support group 12 months, once weekly (2) Usual care	(1) NRS (2) POMS (3) NA (4) NA (5) NA (6) Dropouts	(1) Larger decrease in hypnosis than in support group (ES NR, <i>P</i> < .05) and usual care (ES NR, <i>P</i> < .02) (2) NR (3) NA (4) NA (5) NA (5) NA (5) NA (5) NA (5) NA (6) 15/50 (Hypnosis & support group) vs 11/36 (usual care) died

Abbreviations: BDI, Beck Depression Inventory, CES-D, Center for Epidemiologic Studies Depression Scale; ES, effect size; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue; HADS-A, Hospital Anxiety and Depression Scale—Anxiety; HFRDIS, Hot Flash Related Daily Interference Scale; NA, not assessed; NR, not reported; NRS, Numerical Rating Scale; NS, no significant group difference; POMS, Profile of Mood State; STAI, State-Trait Anxiety Inventory; VAS, Visual Analog Scale.

Table 2. Risk of Bias Assessment of the Included Studies Using the Cochrane Risk of Bias Tool.

				Bias			
Author, Year	Random Sequence Generation (Selection Bias)	Allocation Concealment (Selection Bias)	Blinding of Participants and Personnel (Performance Bias)	Blinding of Outcome Assessment (Detection Bias)	Incomplete Outcome Data (Attrition Bias)	Selective Reporting (Reporting Bias)	Other Bias
Butler et al, 2009 ²⁸	Low risk	Unclear	High risk	Unclear	High risk	High risk	Low risk
Elkins et al, 2008 ²⁹	Low risk	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Elkins et al, 2012 ³⁰	Low risk	Low risk	Unclear	Unclear	Low risk	High risk	Low risk
Laidlaw et al, 2005 ³¹	Unclear	Unclear	Unclear	Unclear	High risk	Low risk	Low risk
Lang et al, 2006 ³²	Low risk	Low risk	Unclear	High risk	Low risk	Low risk	Low risk
MacLaughlan David et al, 2013 ³³	Low risk	Unclear	High risk	High risk	High risk	Low risk	High risk
Montgomery et al, 2002 ³⁴	High risk	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Montgomery et al, 2007 ³⁵	Low risk	Unclear	High risk	Low risk	Low risk	Low risk	Low risk
Montgomery et al, 2009 ³⁶	Low risk	Low risk	High risk	Unclear	Low risk	Low risk	Low risk
Montgomery et al, 2014 ³⁷	Low risk	Unclear	High risk	Low risk	Low risk	Unclear	Low risk
Schnur et al, 2008 ³⁸	Low risk	Unclear	Unclear	Low risk	Low risk	Low risk	Low risk
Schnur et al, 2009 ³⁹	Low risk	Low risk	High risk	Low risk	Low risk	Low risk	Low risk
Spiegel et al, 1983 ⁴⁰	Unclear	Unclear	Unclear	Unclear	High risk	Low risk	Low risk

safety data.³² This study reported 3 adverse events in the hypnosis group (all hematomas) compared to 7 adverse events in the standard care group and 11 adverse events in the attention control groups. Differences in proportions were insignificant.

Women With Breast Cancer Undergoing Breast Cancer Surgery. An RCT assessed the effects of preoperative hypnosis on postoperative pain, distress, fatigue, nausea, and vomiting. Hypnosis induced a significantly greater reduction on all variables compared to attention control.

Women With Breast Cancer Undergoing Radiotherapy. One RCT reported significant effects of hypnosis combined with cognitive—behavioral therapy on psychological distress³⁹; and 2 RCTs on fatigue^{34,37} associated with radiotherapy. One RCT reported that no serious adverse events occurred³⁹; another RCT reported that no adverse events related to hypnosis combined with cognitive—behavioral therapy occurred.³⁸

Women With and Without a History of Breast Cancer Experiencing Hot Flashes. Two RCTs assessed psychological distress and hot flashes in breast cancer survivors. 29,33 Compared to no treatment, depression, anxiety, and hot flashes significantly decreased after hypnosis.²⁹ Compared to Gabapentin, no group differences were found regarding number and severity of hot flashes, and hot flash-related interference.31 While adverse events were not reported in total in 1 RCT, no patients in either group dropped out of the study due to adverse events (27). In the other RCT, no patient reported hypnosis-related adverse events while 2 patients dropped out due to side effects in the Gabapentin group.³³ A third RCT assessed hot flashes in postmenopausal women without a history of breast cancer. Compared to attention control, hypnosis reduced subjectively and objectively measured hot flash frequency, hot flash severity, and hot flash-related interference. 30 Twenty-five minor adverse events were reported but none of them was associated with the interventions.³⁰

Cramer et al

Women With Metastatic Breast Cancer. Two RCTs reported significant effects on pain in women with metastatic breast cancer. ^{28,40} While both RCTs combined hypnosis with supportive group therapy, in one of them this intervention was more effective than supportive group therapy alone. ⁴⁰ A third RCT reported effects of hypnosis compared to no treatment on distress. ³¹ All 3 studies reported health-related dropouts. The number of dropouts due to death or illness was comparable between groups in one study, ³¹ higher in the hypnosis group in one study, ⁴⁰ and lower in the third study. ²⁸

Discussion

This systematic review found evidence for reduced pain and distress associated with diagnostic breast biopsy and for reduced pain, distress, fatigue, and nausea associated with breast cancer surgery after preoperative hypnosis compared to attention control; for effects of hypnosis combined with cognitive-behavioral therapy on radiotherapy-associated distress and fatigue in women with breast cancer; for effects on hot flashes in women with and without a history of breast cancer experiencing hot flashes; and for effects of hypnosis—either alone or combined with supportive group therapy—on pain and distress in women with metastatic breast cancer. No studies on effects in women with breast cancer during chemotherapy could be located. The available safety data suggest no differences in adverse events between intervention and control groups. However, future RCTs should ensure more rigorous reporting of safety data.

Agreements With Prior Systematic Reviews

This is the first systematic review on hypnosis for symptoms related to breast cancer, its diagnostic procedures, or treatment. The results of this review are partly in line with previous reviews on hypnosis in related patient samples. 41-43 A qualitative review on hypnotic analgesia in adults included 2 studies on breast biopsy or cancer surgery and found effects on pain and distress.⁴³ A meta-analysis on hypnosis for surgery patients concluded that hypnosis can decrease negative affect and pain. 41 A more recent metaanalysis on hypnosis in various medical procedures found large effects on distress. 42 A systematic review on hypnosis for the management of chemotherapy-related side effects has concluded, mainly based on pediatric patients, that hypnosis can reduce chemotherapy-related nausea and vomiting. 44 This finding has not yet been replicated in women with breast cancer. No reviews on the effects of hypnosis during radiotherapy, in women with metastatic cancer, or cancer survivors could be located.

External and Internal Validity

All included studies were conducted in US medical centers. Patients were mainly Caucasians, but members of ethnic minorities were also included in all studies. Four studies included patients undergoing diagnostic surgery; however, only one study also included patients undergoing therapeutic surgery. Two studies included patients undergoing radiotherapy, 2 studies included breast cancer survivors, and 3 studies included women with metastatic breast cancer. Given that effects of therapeutic interventions for hot flashes are comparable in women with and without a history of breast cancer, 45 it was post hoc decided to also include studies on postmenopausal women with hot flashes without prior breast cancer.

The results of this review are applicable to a considerable number of women with metastatic breast cancer, women experiencing hot flashes, and women undergoing diagnostic breast biopsy or radiotherapy in clinical practice although the limited number of available studies precludes definite conclusions on applicability. External validity is limited for patients undergoing therapeutic breast cancer surgery and for breast cancer survivors.

Overall, most included studies had low risk of bias. However, allocation concealment was unclear in 7 studies, ^{28,29,31,34,35,38,40} and randomization was inadequate or unclear in 3 studies. ^{31,34,40} Blinding of outcome assessors was adequate in 4 studies. Blinding patients or care providers in hypnosis studies might not be possible at all. Therefore, internal validity of the results might be judged acceptable.

Strengths and Weaknesses

This is the first available systematic review on hypnosis for symptoms related to breast cancer and its diagnostic or therapeutic procedures. Patients undergoing a wide range of different diagnostic or therapeutic procedures as well as women with metastatic breast cancer and breast cancer survivors were included. Overall risk of bias was mainly low. Hypnosis interventions and control conditions were comparable at least for studies on patients undergoing breast biopsy and radiotherapy, thus reducing heterogeneity of analyses.

The primary limitation of this review is the small total number of eligible RCTs. Especially the results for patients undergoing breast cancer surgery and breast cancer survivors rely on single studies and should be regarded as very preliminary. Hypnosis was combined with cognitive—behavioral therapy in both trials in patients undergoing radiotherapy. Therefore, the specific effects of hypnosis and cognitive—behavioral therapy in this patient population could not be assessed. While hypnosis did not seem to be associated with severe adverse events, more rigorous reporting of safety data is needed in future studies. Hypnosis was compared to no treatment or attention control in most trials. While the results suggest efficacy of hypnotic interventions, head-to head comparisons with other effective psychosocial interventions are still rare.

Implications for Further Research

The included trials give important hints for effects of hypnosis in breast cancer patients in a variety of settings. However, as only very few and heterogeneous RCTs were available, more research is needed. These studies should ensure rigorous methodology and reporting, mainly adequate randomization, allocation concealment, intention-totreat analysis, and blinding of at least outcome assessors.⁴⁶ Especially the effectiveness of hypnosis for breast cancer patients undergoing chemotherapy has not been investigated yet. It would further be interesting to investigate whether hypnosis combined with cognitive-behavioral therapy really is superior to hypnosis alone in patients undergoing radiotherapy, as the authors of those studies suppose. 36,38,39 Furthermore, replications of positive RCTs are needed to consolidate the evidence for effects of hypnosis in women undergoing diagnostic breast biopsy, breast cancer surgery, in women with metastatic breast cancer, and breast cancer survivors. Since the findings on effects of hypnosis on hot flashes are based on 2 RCTs in breast cancer survivors^{29,33} and 1 RCT in women without a history of breast cancer,30 a large-scale RCT on hot flashes in breast cancer survivors is needed to underpin the positive findings.

Conclusions

While more research is needed to underpin these results, hypnosis can be considered as an ancillary intervention in the management of breast cancer—related symptoms, namely, for women undergoing diagnostic breast biopsy or breast cancer surgery, women with metastatic breast cancer, breast cancer survivors, and postmenopausal women with and without a history of breast cancer experiencing hot flashes. Furthermore, hypnosis combined with cognitive—behavioral therapy could be considered in women undergoing breast cancer radiotherapy.

Authors' Note

The funding agency did not have any influence on the design or conduct of the review; the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the article.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the Rut- and Klaus-Bahlsen Foundation.

References

- Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide (IARC CancerBase No. 11). Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr. Published 2013. Accessed August 26, 2014.
- Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
- 3. Scott DW. Anxiety, critical thinking and information processing during and after breast biopsy. *Nurs Res.* 1983;32:24-28.
- Carpenter JS, Andrykowski MA, Sloan P, et al. Postmastectomy/postlumpectomy pain in breast cancer survivors. J Clin Epidemiol. 1998;51:1285-1292.
- Katz J, Poleshuck EL, Andrus CH, et al. Risk factors for acute pain and its persistence following breast cancer surgery. *Pain*. 2005;119:16-25.
- Boehmke MM, Dickerson SS. Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs. 2005;28:382-389.
- Mann A. A continuing postoperative complication: nausea and vomiting—who is affected, why, and what are the contributing factors? A review. CRNA. 1998;9:19-29.
- Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L.
 The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. *Cancer Nurs.* 1994;17:367-378.
- Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue: a critical appraisal. *Eur J Cancer*. 2006;42:846-863.
- Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. *Psychooncology*. 2001;10:19-28.
- Schmitz KH, Speck RM, Rye SA, DiSipio T, Hayes SC. Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through Study. *Cancer*. 2012;118:2217-2225.
- Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. *J Clin Oncol*. 2000;18:743-753.
- Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. *Cancer*. 1998;82:1682-1691.
- Chung F, Ritchie E, Su J. Postoperative pain in ambulatory surgery. *Anesth Analg.* 1997;85:808-816.
- Green JP, Barabasz AF, Barrett D, Montgomery GH. Forging ahead: the 2003 APA Division 30 definition of hypnosis. *Int J Clin Exp Hypn*. 2005;53:259-264.
- Elkins G. Hypnotic Relaxation Therapy: Principles and Applications. New York, NY: Springer; 2013.
- Spiegel D, Moore R. Imagery and hypnosis in the treatment of cancer patients. Oncology (Williston Park). 1997;11:1179-1189
- Montgomery GH, DuHamel KN, Redd WH. A meta-analysis of hypnotically induced analgesia: how effective is hypnosis? *Int J Clin Exp Hypn*. 2000;48:138-153.

Cramer et al 15

 Fortuin AA. Hypnotherapy as antiemetic treatment in cancer chemotherapy. Recent Results Cancer Res. 1988;108:112-116

- Montgomery GH, Hallquist MN, Schnur JB, David D, Silverstein JH, Bovbjerg DH. Mediators of a brief hypnosis intervention to control side effects in breast surgery patients: response expectancies and emotional distress. *J Consult Clin Psychol.* 2010;78:80-88.
- Kirsch I. Hypnosis and placebos: response expectancy as a mediator of suggestion effects. *Anales de Psicología*. 1999:15:99-110.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151:264-269.
- Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. West Sussex, England: Wiley; 2010.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336:924-926.
- Enqvist B, Bjorklund C, Engman M, Jakobsson J. Preoperative hypnosis reduces postoperative vomiting after surgery of the breasts. A prospective, randomized and blinded study. *Acta Anaesthesiol Scand*. 1997;41:1028-1032.
- Oddby-Muhrbeck E, Jakobsson J, Enquist B. Implicit processing and therapeutic suggestion during balanced anaesthesia. *Acta Anaesthesiol Scand*. 1995;39:333-337.
- Lew MW, Kravits K, Garberoglio C, Williams AC. Use of preoperative hypnosis to reduce postoperative pain and anesthesia-related side effects. *Int J Clin Exp Hypn*. 2011;59: 406-423.
- 28. Butler LD, Koopman C, Neri E, et al. Effects of supportive-expressive group therapy on pain in women with metastatic breast cancer. *Health Psychol*. 2009;28:579-587.
- Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. *J Clin Oncol*. 2008;26:5022-5026.
- 30. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. *Menopause*. 2013;20:291-298.
- 31. Laidlaw T, Bennett BM, Dwivedi P, et al. Quality of life and mood changes in metastatic breast cancer after training in self-hypnosis or Johrei: a short report. *Contemp Hypn*. 2005;22:84-93.
- 32. Lang EV, Berbaum KS, Faintuch S, et al. Adjunctive self-hypnotic relaxation for outpatient medical procedures: a prospective randomized trial with women undergoing large core breast biopsy. *Pain*. 2006;126:155-164.

- 33. Maclaughlan David S, Salzillo S, Bowe P, et al. Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. *BMJ Open*. 2013;3:e003138.
- Montgomery GH, Weltz CR, Seltz M, Bovbjerg DH. Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients. *Int J Clin Exp Hypn*. 2002;50:17-32.
- 35. Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. *J Natl Cancer Inst*. 2007;99:1304-1312.
- 36. Montgomery GH, Kangas M, David D, et al. Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis. *Health Psychol*. 2009;28:317-322.
- Montgomery GH, David D, Kangas M, et al. Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer. *J Clin Oncol*. 2014;32:557-563.
- Schnur JB, Bovbjerg DH, David D, et al. Hypnosis decreases presurgical distress in excisional breast biopsy patients. *Anesth Analg.* 2008;106:440-444.
- Schnur JB, David D, Kangas M, Green S, Bovbjerg DH, Montgomery GH. A randomized trial of a cognitive-behavioral therapy and hypnosis intervention on positive and negative affect during breast cancer radiotherapy. *J Clin Psychol*. 2009;65:443-455.
- Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. *Psychosom Med.* 1983;45: 333-339.
- 41. Montgomery GH, David D, Winkel G, Silverstein JH, Bovbjerg DH. The effectiveness of adjunctive hypnosis with surgical patients: a meta-analysis. *Anesth Analg.* 2002;94:1639-1645.
- 42. Schnur JB, Kafer I, Marcus C, Montgomery GH. Hypnosis to manage distress related to medical procedures: a meta-analysis. *Contemp Hypn*. 2008;25:114-128.
- 43. Stoelb BL, Molton IR, Jensen MP, Patterson DR. The efficacy of hypnotic analgesia in adults: a review of the literature. *Contemp Hypn*. 2009;26:24-39.
- Richardson J, Smith JE, McCall G, Richardson A, Pilkington K, Kirsch I. Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence. *Eur J Cancer Care (Engl)*. 2007;16:402-412.
- Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. *Menopause*. 2008;15:655-660.
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol*. 2010;63:834-840.